MissionIR Articles

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with…

Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48%…

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity…

Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a…

In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and…

Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug…

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM)…

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, announced the successful completion of its Phase 1a clinical trial for LP-184 (NCT05933265), which met all primary endpoints, showing a favorable safety and pharmacokinetic profile with early…

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, reported second-quarter 2025 results while outlining clinical progress, intellectual property gains, and new developments in its…

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has introduced predictBBB.ai(TM), a publicly available AI module designed to predict blood-brain barrier (“BBB”) permeability for small-molecule…

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating…

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has unveiled a new artificial intelligence module designed to predict the effectiveness of cancer treatment combinations…